MGF
Mechano Growth Factor — Muscle Repair, IGF-1 Splicing & Regenerative Research
PRECLINICAL & HUMAN EXPRESSION EVIDENCE
NOT ESTABLISHED IN HUMANS
NOT APPROVED
What Is MGF?
Mechano Growth Factor (MGF) is a term associated with a mechanically responsive splice variant of the insulin-like growth factor-1 (IGF-1) gene. The terminology is more complicated than many peptide websites suggest.
In humans, mechanical stress and muscle injury can influence expression of an IGF-1 splice variant commonly called IGF-1Ec. The name “MGF” has been used to describe several related — but not necessarily identical — things: the IGF-1Ec messenger-RNA splice variant, the corresponding IGF-1 prohormone, and a synthetic 24-amino-acid peptide corresponding to part of the IGF-1Ec E-domain.
A major scientific review emphasized that these different meanings have created significant confusion in the literature. Researchers have not definitively established that the synthetic 24-amino-acid peptide sold as “MGF” exists naturally in the body as a stable, independent peptide in the same form.
Important: Evidence that human muscle naturally increases expression of an IGF-1 splice variant after exercise does not establish that injecting synthetic MGF reproduces that biological process.
Why Are Researchers Interested?
MGF became interesting because skeletal muscle responds to mechanical loading and injury by activating complex repair pathways. Researchers have investigated MGF-related biology in areas including:
Human muscle-biopsy studies have shown that IGF-1Ec/MGF-related gene expression can change following exercise-induced muscle damage. That makes MGF biology scientifically interesting. What remains unproven is whether administering a synthetic MGF peptide to people produces clinically meaningful muscle growth, recovery, or injury repair.
What The Research Suggests
Human Muscle Can Increase MGF-Related Gene Expression After Exercise
One important human study evaluated ten healthy men following exercise-induced muscle damage. Muscle biopsies were collected before exercise and at several time points afterward. Researchers observed a rapid and temporary increase in IGF-1Ec/MGF messenger-RNA expression, followed by later increases in other IGF-1 isoforms.
This supports the idea that the body's IGF-1 system responds locally to mechanical stress. However, the participants were not given synthetic MGF; researchers were measuring the body's own gene-expression response. That distinction is critical.
MGF Has Been Proposed to Influence Muscle Satellite Cells
Muscle satellite cells are stem-like cells involved in repair and adaptation of skeletal muscle. Early laboratory studies suggested that synthetic MGF-related peptides might increase myoblast proliferation, delay differentiation, influence migration of muscle precursor cells, and potentially participate in early stages of muscle repair.
For example, laboratory research involving human muscle precursor cells found that a synthetic MGF E-domain peptide increased cell migration and altered molecular pathways involved in movement of those cells. Another study reported effects on human muscle-progenitor cells and their fusion potential under laboratory conditions. These are cell-based findings, not evidence of therapeutic effectiveness in patients.
Some Experiments Have Failed to Confirm the Proposed MGF Effect
The preclinical evidence is not completely consistent. A 2014 study specifically attempted to investigate the synthetic MGF peptide's proposed effects on myoblasts and primary muscle stem cells. Researchers reported no apparent effect on proliferation, differentiation, or survival in the experimental systems they tested.
This is particularly important because earlier research had suggested that synthetic MGF directly promoted satellite-cell or myoblast proliferation. The conflicting results mean that even the preclinical mechanism remains unsettled.
The Relationship Between Natural IGF-1Ec and Synthetic MGF Is Still Debated
A major Endocrine Society review examined the entire “MGF hypothesis.” The authors concluded that although IGF-1 splice variants clearly respond to tissue damage, there was insufficient evidence showing that the body naturally generates the same stable 24-amino-acid peptide commonly referred to as synthetic MGF.
The review stated that no analogous independent peptide product had been definitively identified in cultured cells, biological fluids, or living tissues. This means the following statements are not equivalent: “Exercise increases IGF-1Ec expression” has human biological evidence; “Injected synthetic MGF reproduces the body's muscle-repair response” has not been established.
Cartilage and Joint Research Is Preclinical
MGF-related biology has also been investigated in cartilage. Researchers have detected IGF-1Ec/MGF-related expression in growth-plate tissue and studied synthetic MGF peptides in cartilage cells.
A more recent review concluded that MGF may participate in mechanical responses and tissue-repair pathways involving cartilage, but also described the field as controversial, with biological mechanisms still incompletely understood. There is currently no established human clinical treatment involving MGF for arthritis, cartilage injuries, or joint repair.
Evidence At A Glance
Exercise-Responsive IGF-1Ec Expression
Human muscle-biopsy studies show changes in IGF-1Ec/MGF-related expression following exercise and muscle damage.
Synthetic MGF and Muscle Cells
Some laboratory studies report increased proliferation or migration of muscle precursor cells, while other experiments have failed to reproduce meaningful effects.
Human Muscle Growth
There are no adequate controlled human trials demonstrating that administered MGF increases muscle mass or strength.
Injury Recovery
Claims involving faster recovery, tendon healing, ligament repair, or rehabilitation remain unsupported by adequate human clinical evidence.
Aging / Sarcopenia
Biological research exists, but human treatment effectiveness has not been established.
PEG-MGF
FDA states that it has not identified human exposure data involving drug products containing PEG-MGF administered by any route.
Safety & Limitations
The largest safety problem surrounding MGF is straightforward: there is no adequate human clinical safety database for administered synthetic MGF. That means important questions remain unanswered regarding appropriate human exposure, short- and long-term adverse effects, immunogenicity, effects on glucose metabolism, effects on tumor biology, cardiovascular effects, drug interactions, repeated administration, and effects in people with chronic disease. Absence of documented adverse events in controlled trials cannot be used as reassurance when adequate human trials have not been performed.
Growth Signaling Requires Caution
MGF is associated with the broader IGF-1 biological system, which participates in cell proliferation, tissue growth, cell survival, differentiation, and repair signaling. This does not mean MGF has been shown to cause cancer.
However, any experimental compound proposed to influence growth and cellular proliferation requires careful evaluation before long-term safety can be assumed. There is currently insufficient human evidence to determine the consequences of prolonged synthetic MGF exposure.
Product Identity Is a Significant Issue
The term “MGF” can refer to different biological and synthetic materials. Researchers have specifically warned that the terminology has been used inconsistently for IGF-1Ec mRNA, the IGF-1Ec propeptide, and a synthetic 24-amino-acid E-domain peptide.
That creates an important product-quality question: what exactly is in a vial labeled “MGF”? Evidence involving one molecular form should not automatically be applied to another.
PEG-MGF Requires Even More Caution
PEG-MGF refers to a synthetic MGF-related peptide that has been chemically modified through PEGylation — attachment of polyethylene glycol. PEGylation is generally intended to change properties such as peptide stability and clearance. This means PEG-MGF is not simply identical to unmodified MGF.
FDA states that it has not identified human exposure data for drug products containing PEG-MGF administered through any route. FDA also identifies concerns involving potential immunogenicity, peptide-related impurities, API characterization, and product complexity. Therefore, claims that PEG-MGF is safer, more effective, longer-lasting in humans, better for muscle growth, or clinically proven are not supported by adequate human clinical evidence.
Regulatory Status
No. MGF is not FDA-approved for muscle growth, sarcopenia, athletic recovery, injury repair, tendon healing, ligament repair, bodybuilding, anti-aging, or any other therapeutic indication. FDA has previously specifically identified Mechano Growth Factor among substances that were not FDA-approved for use in humans in enforcement actions involving bodybuilding products.
This area requires careful wording because MGF and PEG-MGF currently have different FDA compounding histories. As of FDA's May 14, 2026 update, unmodified Mechano Growth Factor (MGF) appears in 503A Category 3 — Bulk Drug Substances Nominated Without Adequate Support. Category 3 should not be interpreted as FDA approval or endorsement for compounding; it means the nomination did not contain adequate supporting information for FDA's evaluation process.
PEG-MGF had previously appeared in FDA's Category 2 safety-risk framework. FDA reported in April 2026 that the nomination had been withdrawn and that the agency intended to consult its Pharmacy Compounding Advisory Committee regarding PEG-MGF before the end of February 2027. FDA's current safety page still warns that compounded PEG-MGF may present significant immunogenicity and product-characterization concerns, while noting that FDA has identified no human exposure data.
Not FDA-Approved for Any Therapeutic Indication
MGF is not FDA-approved for muscle growth, sarcopenia, athletic recovery, injury repair, tendon healing, ligament repair, bodybuilding, anti-aging, or any other therapeutic indication. FDA has previously specifically identified Mechano Growth Factor among substances that were not FDA-approved for use in humans in enforcement actions involving bodybuilding products.
Unmodified MGF — 503A Category 3
As of FDA's May 14, 2026 update, Mechano Growth Factor (MGF) appears in 503A Category 3 — Bulk Drug Substances Nominated Without Adequate Support. Category 3 should not be interpreted as FDA approval or endorsement for compounding. It means the nomination did not contain adequate supporting information for FDA's evaluation process.
PEG-MGF — Compounding Safety Concerns
PEG-MGF had previously appeared in FDA's Category 2 safety-risk framework. FDA reported in April 2026 that the nomination had been withdrawn and that the agency intended to consult its Pharmacy Compounding Advisory Committee regarding PEG-MGF before the end of February 2027.
FDA's current safety page still warns that compounded PEG-MGF may present significant immunogenicity and product-characterization concerns, while noting that FDA has identified no human exposure data involving PEG-MGF drug products administered through any route.
Regulatory Status: Not FDA-Approved — Mechano Growth Factor is not FDA-approved for muscle growth, recovery, tissue repair, anti-aging, or any other therapeutic indication. FDA currently lists unmodified MGF in 503A Category 3 as a bulk drug substance nominated without adequate support. FDA has also identified significant unresolved safety concerns involving PEG-MGF. Future regulatory status cannot be predicted.
MGF vs. IGF-1
MGF is frequently marketed as though it were simply a more targeted version of IGF-1. That is misleading. Research involving mature IGF-1 cannot automatically be applied to synthetic MGF, and evidence that exercise activates IGF-1Ec expression does not establish that injecting MGF reproduces natural exercise-induced repair signaling.
IGF-1
Insulin-like growth factor-1 is an established human growth factor involved in growth, cell survival, protein metabolism, muscle biology, and bone biology. The recombinant IGF-1 medication mecasermin has an FDA-approved use for certain children with severe primary IGF-1 deficiency.
MGF / IGF-1Ec
A term associated with an alternatively spliced form of the IGF-1 gene and a proposed synthetic E-domain peptide. Its physiological identity and independent signaling role remain much less clearly established.
PEG-MGF
A chemically modified, PEGylated version of MGF designed to alter the peptide's pharmacological characteristics. PEGylation changes the molecule, and FDA has identified no human exposure data for PEG-MGF drug products.
Why the Difference Matters: Evidence involving natural IGF-1Ec expression or synthetic unmodified MGF should not automatically be presented as evidence for PEG-MGF. Different molecular forms require their own evidence for safety and effectiveness.
MGF & Competitive Athletes
MGF is frequently discussed in bodybuilding and sports-recovery circles. As an investigational growth-factor-related peptide that is not FDA-approved, it is subject to anti-doping rules governing non-approved substances. Competitive athletes should consult the current rules of their governing organization before using any medication, supplement, or investigational compound.
Research & Publications
Mechano-Growth Factor: Tissue Repair & Regeneration Review
Endocrinology — 2010
A major scientific review examining IGF-1 alternative splicing, the MGF hypothesis, satellite-cell biology, synthetic MGF peptides, and important uncertainty over whether the proposed standalone MGF peptide actually exists naturally in vivo.
View MGF Review on PubMedHuman Exercise-Induced MGF Expression
In Vivo — 2009
Researchers obtained repeated muscle biopsies from healthy men after exercise-induced muscle damage and found transient increases in IGF-1Ec/MGF-related expression. The study also evaluated synthetic MGF peptide activity in cultured cells.
View Human Muscle Study on PubMedSynthetic MGF and Human Muscle Precursor Cells
2007
Laboratory research examining a synthetic 24-amino-acid MGF E-domain peptide found effects on migration-related pathways in human muscle precursor cells.
View Muscle Precursor Research on PubMedMGF and Aging Human Muscle Progenitor Cells
Mechanisms of Ageing and Development — 2011
Laboratory research examining MGF-related responses in human muscle progenitor cells from different age groups.
View Aging & Muscle Research on PubMedStudy Failing to Replicate Proposed MGF Muscle Effects
American Journal of Physiology — Endocrinology and Metabolism — 2014
Researchers investigated the synthetic MGF peptide in multiple muscle-cell systems and reported no apparent effect on myoblasts or primary muscle stem cells, providing an important counterpoint to earlier positive findings.
View MGF Replication Study on PubMedMGF in Cartilage Biology
PLOS ONE — 2013
Preclinical research examining IGF-1Ec/MGF expression in growth-plate cartilage and the effects of synthetic MGF peptide on cartilage cells.
View Cartilage Study on PubMedModern Review of MGF and Cartilage Repair
2023
A contemporary review discussing MGF in cartilage and chondrocyte biology while emphasizing continuing controversy and unresolved mechanisms.
View 2023 MGF Review on PubMedFDA — Current 503A Bulk Drug Substance Categories
U.S. Food and Drug Administration — Updated May 14, 2026
FDA's current list places Mechano Growth Factor (MGF) in 503A Category 3 — Bulk Drug Substances Nominated Without Adequate Support.
View Current FDA 503A ListFDA — PEG-MGF Compounding Safety Concerns
U.S. Food and Drug Administration — Current Resource
FDA states that compounded PEG-MGF may present significant immunogenicity and peptide-characterization concerns and that it has identified no human exposure data involving PEG-MGF drug products.
View FDA PEG-MGF Safety ResourceMGF is a scientifically interesting part of the IGF-1 and muscle-repair research field, but natural MGF-related biology should not be confused with evidence supporting injected synthetic MGF products.
Human research demonstrates that IGF-1Ec-related gene expression can respond to exercise and muscle injury. Laboratory and animal studies have investigated synthetic MGF peptides for effects involving muscle precursor cells, tissue repair, cartilage, and regeneration. However, the preclinical findings are mixed, the precise physiological identity of the proposed independent MGF peptide remains debated, and adequate human treatment trials demonstrating muscle growth, enhanced recovery, injury repair, or anti-aging benefits are lacking.
PEG-MGF has even less clinical evidence. FDA states that it has identified no human exposure data involving drug products containing PEG-MGF. MGF is not FDA-approved for any therapeutic indication. This page is provided for educational purposes only. MGF is not offered for sale, prescription, or distribution through this website.